148 related articles for article (PubMed ID: 22364811)
1. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.
Gater A; Heron L; Abetz-Webb L; Coombs J; Simmons J; Guilhot F; Rea D
Leuk Res; 2012 Jul; 36(7):817-25. PubMed ID: 22364811
[TBL] [Abstract][Full Text] [Related]
2. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
3. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.
Eliasson L; Clifford S; Barber N; Marin D
Leuk Res; 2011 May; 35(5):626-30. PubMed ID: 21095002
[TBL] [Abstract][Full Text] [Related]
4. Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients.
Boons CCLM; Tromp VNMF; Neppelenbroek NJM; Timmers L; van Schoor NM; Swart EL; Hendrikse NH; Janssen JJWM; Hugtenburg JG
Acta Oncol; 2019 Jun; 58(6):891-896. PubMed ID: 30905234
[No Abstract] [Full Text] [Related]
5. New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia.
le Coutre P; Schwarz M; Kim TD
Clin Cancer Res; 2010 Mar; 16(6):1771-80. PubMed ID: 20197479
[TBL] [Abstract][Full Text] [Related]
6. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
7. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
9. [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
Molnár L; Losonczy H
Orv Hetil; 2002 Oct; 143(42):2379-84. PubMed ID: 12440260
[TBL] [Abstract][Full Text] [Related]
10. Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Breccia M; Efficace F; Alimena G
Leuk Res; 2012 Jul; 36(7):804-5. PubMed ID: 22459331
[No Abstract] [Full Text] [Related]
11. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
12. Flying under the radar: the new wave of BCR-ABL inhibitors.
Quintás-Cardama A; Kantarjian H; Cortes J
Nat Rev Drug Discov; 2007 Oct; 6(10):834-48. PubMed ID: 17853901
[TBL] [Abstract][Full Text] [Related]
13. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
14. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
15. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
16. What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
Deininger MW; Manley P
Leuk Res; 2012 Mar; 36(3):253-61. PubMed ID: 21996558
[TBL] [Abstract][Full Text] [Related]
17. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
Deininger MW; Druker BJ
Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
[TBL] [Abstract][Full Text] [Related]
18. Glivec and CML: a lucky date.
Saglio G; Cilloni D; Rancati F; Boano L
J Biol Regul Homeost Agents; 2004; 18(2):246-51. PubMed ID: 15739279
[TBL] [Abstract][Full Text] [Related]
19. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.
Zámečníkova A
Expert Rev Hematol; 2010 Feb; 3(1):45-56. PubMed ID: 21082933
[TBL] [Abstract][Full Text] [Related]
20. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
Keller G; Schafhausen P; Brummendorf TH
Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
